Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?

Publication date: April 2018Source: Cor et Vasa, Volume 60, Issue 2Author(s): Radovan Jirmář, Petr WidimskýAbstractThe aim of this review article is to make readers aware of the risk of an inadequate antiplatelet effect of enteric-coated formulations of aspirin. Judging by data from studies published to date and exploring the efficacy of various aspirin formulations, there exist sufficient evidences only of a plain form of aspirin absorbed in the stomach. The implication is that patients with coronary heart disease (CHD) should be treated exclusively with the standard formulation of aspirin.
Source: Cor et Vasa - Category: Cardiology Source Type: research